Literature DB >> 7088112

Respiratory syncytial viral infection in infants with congenital heart disease.

N E MacDonald, C B Hall, S C Suffin, C Alexson, P J Harris, J A Manning.   

Abstract

Occasional reports have suggested that infants with congenital heart disease may have an increased risk of severe illness from respiratory syncytial virus (RSV) infection. We prospectively studied 699 infants hospitalized during the winters of 1976 through 1980, when RSV was prevalent in the community; 229 of these infants had proved RSV infections acquired either before admission or during hospitalization; 27 had both congenital heart disease and RSV infection, and 46 had congenital heart disease without RSV infection. Infected infants with congenital heart disease had significantly more severe illness than those without congenital heart disease, as judged by the requirement for intensive care and assisted ventilation and by the mortality rate (37 per cent vs. 1.5 per cent, P less than 0.01). The infection was acquired nosocomially by 21 per cent of infected infants; the mortality rate from nosocomial infection was also higher in infants with congenital heart disease (44 per cent vs. 5 per cent, P less than 0.01). Pulmonary hypertension was the one condition particularly associated with severe RSV illness. Eight of the 11 infants (73 per cent) with congenital heart disease and pulmonary hypertension died during their RSV illness. The courses in infants with congenital heart disease with and without RSV infection were also compared. Their ages, types of cardiac lesions, and incidence of pulmonary hypertension were similar, but the infants with RSV infection had a higher mortality rate (37 per cent vs. 6.5 per cent, P less than 0.1).

Entities:  

Mesh:

Year:  1982        PMID: 7088112     DOI: 10.1056/NEJM198208123070702

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  128 in total

Review 1.  Current research on respiratory viral infections: Third International Symposium.

Authors:  A C Schmidt; R B Couch; G J Galasso; F G Hayden; J Mills; B R Murphy; R M Chanock
Journal:  Antiviral Res       Date:  2001-06       Impact factor: 5.970

2.  Ventricular Septal Defect.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  1999-12

3.  Risk factors for hospitalization due to respiratory syncytial virus infection among infants in the Basque Country, Spain.

Authors:  G Cilla; A Sarasua; M Montes; N Arostegui; D Vicente; E Pérez-Yarza; E Pérez-Trallero
Journal:  Epidemiol Infect       Date:  2006-06       Impact factor: 2.451

Review 4.  The respiratory syncitial virus and its role in acute bronchiolitis.

Authors:  M L Everard; A D Milner
Journal:  Eur J Pediatr       Date:  1992-09       Impact factor: 3.183

5.  Evaluation of three rapid enzyme immunoassays and cell culture for detection of respiratory syncytial virus.

Authors:  J Mendoza; A Rojas; J M Navarro; C Plata; M de la Rosa
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-05       Impact factor: 3.267

6.  Pediatric infections.

Authors:  N E Macdonald
Journal:  Can J Infect Dis       Date:  1992-03

7.  Changes in cardiac output and stroke volume as measured by non-invasive CO monitoring in infants with RSV bronchiolitis.

Authors:  Julie Caplow; Sarah C McBride; Garry M Steil; Jackson Wong
Journal:  J Clin Monit Comput       Date:  2012-04-24       Impact factor: 2.502

Review 8.  Lower airway obstruction in the PICU.

Authors:  S A Kecskes
Journal:  Indian J Pediatr       Date:  1990 Mar-Apr       Impact factor: 1.967

9.  Evaluation of immunofluorescence, two enzyme immunoassays and the shell-vial assay for detection of respiratory syncytial virus.

Authors:  J Mendoza; J M Navarro; A Rojas; M de la Rosa
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-01       Impact factor: 3.267

10.  Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge.

Authors:  J S Kahn; A Roberts; C Weibel; L Buonocore; J K Rose
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.